Pharming Group N.V. (AMS:PHARM)

Market Cap	777.64M
Revenue (ttm)	289.37M
Net Income (ttm)	-6.98M
Shares Out	685.15M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	55.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,469,579
Average Volume	10,642,483
Open	1.134
Previous Close	1.135
Day's Range	1.125 - 1.163
52-Week Range	0.656 - 1.410
Beta	0.56
RSI	44.28
Earnings Date	Nov 6, 2025

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 404
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: PHARM

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Financial numbers in USD